EGRX vs. OPTN, RVPH, OTLK, PDSB, VNRX, ALXO, IMRX, ACHL, FGEN, and IMMX
Should you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include OptiNose (OPTN), Reviva Pharmaceuticals (RVPH), Outlook Therapeutics (OTLK), PDS Biotechnology (PDSB), VolitionRx (VNRX), ALX Oncology (ALXO), Immuneering (IMRX), Achilles Therapeutics (ACHL), FibroGen (FGEN), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry.
Eagle Pharmaceuticals vs.
OptiNose (NASDAQ:OPTN) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
Eagle Pharmaceuticals has a net margin of 0.00% compared to OptiNose's net margin of -41.16%.
OptiNose has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.
85.6% of OptiNose shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 2.3% of OptiNose shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, OptiNose had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for OptiNose and 0 mentions for Eagle Pharmaceuticals. OptiNose's average media sentiment score of 1.94 beat Eagle Pharmaceuticals' score of 0.00 indicating that OptiNose is being referred to more favorably in the media.
OptiNose presently has a consensus target price of $16.67, suggesting a potential upside of 188.85%. Given OptiNose's stronger consensus rating and higher probable upside, equities research analysts plainly believe OptiNose is more favorable than Eagle Pharmaceuticals.
Eagle Pharmaceuticals has higher revenue and earnings than OptiNose.
Eagle Pharmaceuticals received 163 more outperform votes than OptiNose when rated by MarketBeat users. Likewise, 66.67% of users gave Eagle Pharmaceuticals an outperform vote while only 63.68% of users gave OptiNose an outperform vote.
Summary
Eagle Pharmaceuticals beats OptiNose on 8 of the 15 factors compared between the two stocks.
Get Eagle Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Eagle Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EGRX) was last updated on 2/22/2025 by MarketBeat.com Staff